Ponsegromab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Ponsegromab
- IMMUNOGLOBULIN G1 (237-ALANINE,238-ALANINE,240-ALANINE), ANTI-(HUMAN GROWTH DIFFERENTIATION FACTOR 15) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06946860 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06946860 .KAPPA.-CHAIN, DIMER
- immunoglobulin g1 237 alanine 238 alanine 240 alanine anti human growth differentiation factor 15 human mus musculus monoclonal pf 06946860 gamma 1 chain disulfide with human mus musculus monoclonal pf 06946860 kappa chain dimer
- immunoglobulin g1 kappa anti homo sapiens growth differentiation factor 15 nsaid activated gene 1 protein placental bone morphogenic protein human mus musculus monoclonal antibody gamma 1 heavy chain human mus musculus 1 449 vh homo sapiens ighv1 69 01 94 ighd ighj1 01 mus musculus ighv1 4 01 70 ighd ighj4 01 87 8 8 13 1 120 ighg1 03 ch1 r97 k 227 ch2 l4 a 237 l5 a 238 g7 a 240 ch3 k107 del 450 121 449 223 214 disulfide with kappa light chain human mus musculus 1 214 homo sapiens igkv3 11 02 92 igkj1 01 mus musculus igkv18 36 01 77 igkj1 01 83 6 3 9 1 107 homo sapiens igkc 01 108 214 dimer 229 229 232 232 bisdisulfide
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS GROWTH/DIFFERENTIATION FACTOR 15 (NSAID-ACTIVATED GENE 1 PROTEIN, PLACENTAL BONE MORPHOGENIC PROTEIN)); HUMAN-MUS MUSCULUS MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN, HUMAN-MUS MUSCULUS (1-449) (VH (HOMO SAPIENS IGHV1-69*01 (94%) (IGHD)-IGHJ1*01) / MUS MUSCULUS IGHV1-4*01 (70%) (IGHD)-IGHJ4*01) (87%)) (8.8.13) (1-120)-IGHG1*03 (CH1(R97>K(227)), CH2(L4>A(237),L5>A(238),G7>A(240)), CH3(K107>DEL(450))) (121-449)) (223-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN, HUMAN-MUS MUSCULUS (1'-214') (HOMO SAPIENS IGKV3-11*02 (92%) IGKJ1*01 / MUS MUSCULUS IGKV18-36*01 (77%) IGKJ1*01 (83%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (229-229'':232-232'')-BISDISULFIDE
- pf 06946860
- Pf-06946860
- PF-06946860
- ponsegromab
- Ponsegromab
- ponsegromab [INN]
- PONSEGROMAB [USAN]
- Ponsegromab [WHO-DD]
- ponsegromab inn
- ponsegromab usan
- ponsegromab who dd
- CAS registry numbers
- 2368950-15-4
- ChEMBL ID
- CHEMBL4650502
- FDA ingredient codes (UNII)
- GXA6PF0254
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ponsegromab
- Type
- Antibody
- Drug name stem
- -mab
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- growth differentiation factor 15
- Gene symbol
- growth differentiation factor 15
Investigated indications
- Condition
- Cachexia
- Highest recorded phase
- 1
- Condition identifier
- HP:0004326
- Subject identifier
- D002100
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 2
- Condition identifier
- HP_0002039
- Highest recorded phase
- 1
- Condition identifier
- HP_0004326
- Condition identifier
- HP_0004326
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- Asn-300 $ Asn-300''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYNIDWVRQAPGQGLEWMGGINPIFGTAFYNQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCRTSQSVHNYLAWYQQKPGQAPRLLIYDASTRADGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFWSWPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 147-203 $ 147''-203'' $ 214'-223 $ 214'''-223'' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-300 $ Asn-300''
Related records
Trials (8)
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss
- A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults
- Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants
- Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
- Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
- Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
- Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
In development for (1)
- Heart failure Phase 2